Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS
Published
Conference Paper
Full Text
Duke Authors
Cited Authors
- Konopleva, M; Hogge, DE; Rizzieri, DA; Cirrito, TP; Liu, JS; Kornblau, SM; Grable, M; Hwang, I-R; Borthakur, G; Mankin, A; Bivins, C; Garcia-Manero, G; Kadia, T; Harris, D; Ravandi, F; Andreeff, M; Cortes, JE; Niecestro, R; Bergstein, I; Kantarjian, HM; Frankel, AE
Published Date
- November 19, 2010
Published In
Volume / Issue
- 116 / 21
Start / End Page
- 1351 - 1351
Published By
Pages
- 1
International Standard Serial Number (ISSN)
- 0006-4971
Conference Name
- 52nd Annual Meeting of the American-Society-of-Hematology (ASH)
Conference Location
- Orlando, FL
Conference Start Date
- December 4, 2010
Conference End Date
- December 7, 2010